Goldman Sachs Upgrades Rocket Pharmaceuticals to Neutral, Raises Price Target to $4
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsUpgradesPrice Target
Goldman Sachs analyst Richard Law upgrades Rocket Pharmaceuticals (NASDAQ:RCKT) from Sell to Neutral and raises the price target from $3 to $4.
Goldman Sachs analyst Richard Law upgrades Rocket Pharmaceuticals (NASDAQ:RCKT) from Sell to Neutral and raises the price target from $3 to $4.